Addictions Management
Articles & Whitepapers
-
America`s Painkiller Epidemic and What You Can Do
A new study conducted by the National Safety Council (NSC), along with Indiana’s attorney general has found that 80% of Indiana employers have been impacted by prescription drug misuse and abuse by employees. 80% is a substantial figure, causing some to refer to this trend as a painkiller epidemic. This figure is not unique to Indiana, the NSC notes that the results would likely be ...
-
How Medical Studies are Changing the World
The coronavirus pandemic remains one of the top concerns within the United States. However, Johns Hopkins, and other research centers, are actively working to continue medical research in all ...
News
-
Braeburn receives new Complete Response Letter for Brixadi in the US
Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for its updated New Drug Application (NDA) for Brixadi (buprenorphine) ...
The European Medicines Agency accepts application to extend the Buvidal indication to include treatment of chronic pain
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
Overdose Deaths Accelerating During COVID-19
Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories
Equipment & Solutions
-
Showcase
Buprenorphine Injection
Buvidal® buprenorphine injection depots are indicated for the treatment of opioid dependence within a framework of medical, social and psychological treatment, and intended for use in adults and adolescents aged 16 years or over.
